Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Anticoagulants × Gastrointestinal × Clear all
NCT00443573 2008-05-07

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

ARCA Biopharma, Inc.

Phase 1/2 Suspended
100 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡